



		7:00	8:00	9:00	10:00	11:00	12:00	13:00	14:00	15:00	16:00	17:00	18:00	19:00	20:00	21:00
Makuhari Messe International Conference Hall	Room 1 Convention Hall (2F)				Opening Ceremony				Hot Topics 01 Anti-amyloid therapy for Alzheimer's disease: the time has come		AO-01 Oral Presentation Award Nominee Session (Basic Research)					
	Room 2 International Conference Room (2F)						LS-01 Takeda Pharmaceutical Company Limited				AO-02 Oral Presentation Award Nominee Session (Clinical Research)			Get Together Date & Time: May 31 (Wed), 19:00 - Place: Room Tsuru, 2F Hotel New Otani Makuhari		
	Room 3 201 (2F)				Symposium 01 The current update of restless legs syndrome; from mechanisms to treatment		LS-02 Novartis Pharma K.K.		Symposium 07 Pathogenesis of Parkinson's Disease		O-01 Parkinsonism and Related disorders 1					
	Room 4 301 (3F)						LS-03 Daiichi Sankyo Co., Ltd./UCB Japan Co., Ltd.		Symposium 08 Which treatment should we select in MGI?		O-02 Neuromuscular junction disorders					
	Room 5 304 (3F)				Symposium 02 Knowledge and practical skills in rehabilitation medicine with non - invasive nerve stimulation		LS-04 CANON MEDICAL SYSTEMS CORPORATION		Symposium 09 Current status and prospects of stroke medical care expanding with AI support		O-03 Cerebrovascular disease 1					
	Room 6 302 (3F)				Symposium 03 Overview of autoimmune peripheral neuropathies		LS-05 Kyowa Kirin Co., Ltd.		Neuroscience Frontier Symposium 01 Uncovering molecular link between nutrition and neurodegeneration in ALS		O-04 Neuroscience					
	Room 7 303 (3F)				Symposium 04 Let's talk about the future of young doctors' training		LS-06 PDRadiopharma Inc.		Symposium 10 Hereditary leukodystrophies up to date		O-05 Neuroimmunology 1					
	Room 8 103 (1F)						LS-07 CYBERDYNE, INC.				O-06 Clinical trial and Regenerative medicine					
	Room 9 104 (1F)						LS-08 Sumitomo Pharma Co., Ltd.									
	Room 10 105 (1F)						LS-09 Otsuka Pharmaceutical Co., Ltd.				O-07 Dementia 1					
Tokyo Bay Makuhari Hall	Room 11 No. 3,4 (2F)				Symposium 05 Law, lawsuit and legal issue in neurology		LS-10 Eisai Co., Ltd.		Symposium 11 State-of-the-art in electromyography and neuromuscular ultrasound supported by artificial intelligence		O-08 Headache and Sleep disorders					
	Room 12 No. 5,6 (2F)				Symposium 06 How should we do early diagnosis and early intervention for ALS?		LS-11 CSL Behring K.K.		Lecture Marathon LM-01 LM-02 Lecture Marathon 01 Lecture Marathon 02		O-09 Dementia 2					
	Room 13 No. 7,8 (2F)								Hot Topics 02 Cutting edge of development in stroke therapy How does the researcher achieve the translational research?		O-10 Cerebrovascular disease 2					
	Room 14 No. 9,10 (2F)								Symposium 12 Innovations and achievements in diseases affecting the central nervous system brought in by extensive research on gut microbiota		O-11 Neuroimmunology 2					
	Room 15 No. 11 (2F)						LS-12 Eisai Co., Ltd.									
Makuhari Messe	Poster Session / Exhibition				Poster Preparation / Poster Viewing				Poster Viewing			Poster Presentation / Discussion		Poster Removal		



Plenary Session

Scientific Program

Educational Session

Free Papers(Oral)

Social Event

English Session

Simultaneous Interpretation

Live Streaming Session

		7:00	8:00	9:00	10:00	11:00	12:00	13:00	14:00	15:00	16:00	17:00	18:00	19:00	20:00	21:00	
Makuhari Messe International Conference Hall	Room 1 Convention Hall (2F)			Web Symposium 13 Problem and perspectives for STOR, Cerebrovascular Disease (CVD) Second Five-year Plan		Web PL-01 Plenary Lecture 01 Speaker: Matthew C. Kieman Chair: Satoshi Kuwabara		LS-13 Alexion Pharmaceuticals, Inc.	Web Pr President Lecture Speaker: Satoshi Kuwabara Chair: Takamichi Hattori	Web AW Awards Ceremony / Members	Web Neuroscience Frontier Symposium 02 Gene and cell therapy for neurological diseases						
	Room 2 International Conference Room (2F)		Web Hot Topics 03 All Roads Lead to Cure - from basic researches towards clinical trials for ataxia		O-12 Parkinsonism and Related disorders 2		LS-14 Eisai Co., Ltd.		Japanese Society of Neurology 2022 Awarded Winner Lecture		Web Hot Topics 05 Disease-modifying treatment of PD: What is the rate-limiting factor of drug discovery?				ES-01 Mitsubishi Tanabe Pharma Corporation		
	Room 3 201 (2F)		Web Symposium 14 New developments in the pathogenesis of Alzheimer's disease		O-13 Dementia 3		LS-15 Novartis Pharma K.K.				Web Symposium 20 Road to new treatments for immune peripheral neuropathy						
	Room 4 301 (3F)		Symposium 15 Future of AI in neurological application: from basic research to clinical application		O-14 Neuroimmunology 3		LS-16 UCB Japan Co., Ltd.				Symposium 21 Common Pathological Mechanisms of Psychiatric and Neurodegenerative Diseases Approached from Brain Energy Metabolism and Astrocytes						
	Room 5 304 (3F)		Hot Topics 04 MS brain inflammation; to B or not to B that is the question		O-15 Cerebellar ataxia and Myelopathy		LS-17 Bayer Yakuhin, Ltd.				LB Late Breaking Symposium						
	Room 6 302 (3F)		Web International Education Course Glamping with the Experts for Mastering Movement Disorders		O-16 Motor neuron disease 1		LS-18 FP Pharmaceutical Corporation				Web Symposium 22 Seeing is believing: journey to identify culprit in ALS				ES-02 Eli Lilly Japan K.K.		
	Room 7 303 (3F)		Symposium 16 Telemedicine in home medical care in cooperation with neurologists and multidisciplinary medical professionals		O-17 Neurorehabilitation 1		LS-19 Kyowa Kirin Co., Ltd.				Symposium 23 Neurological dysfunction in post COVID-19 condition/Long COVID: Future issues and countermeasures for neurologists				ES-03 Nihon Medi-Physics Co., Ltd.		
	Room 8 103 (1F)				O-18 Motor neuron disease 2		LS-20 Astellas Pharma Inc.										
	Room 9 104 (1F)				O-19 Peripheral neuropathy and Metabolic disorders 1		LS-21 Sanofi K.K.										
	Room 10 105 (1F)				O-20 Neuropathology												
Tokyo Bay Makuhari Hall	Room 11 No. 3,4 (2F)			Symposium 17 The World of Cerebral Small Vessel Disease. Toward Aggressive Neurology with Cerebral Small Vessel Protection		O-21 Peripheral neuropathy and Metabolic disorders 2		LS-22 Takeda Pharmaceutical Company Limited			Symposium 24 Curable dystonia~recent advance				ES-04 Novartis Pharma K.K.		
	Room 12 No. 5,6 (2F)			Lecture Marathon LM-03 LM-04 Lecture Marathon 03 / Marathon 04		O-22 Cerebrovascular disease 3		LS-23 Sumitomo Pharma Co., Ltd.			Lecture Marathon LM-05 LM-06 Lecture Marathon 05 / Lecture Marathon 06						
	Room 13 No. 7,8 (2F)			Symposium 18 Transition from child to adult health care services for people with neurological diseases: current status and issues		O-23 Muscle diseases 1		LS-24 CHUGAI PHARMACEUTICAL CO., LTD.			Symposium 25 Autoimmune myositis - How much is known?				ES-05 Cosmic Corporation Co., Ltd.		
	Room 14 No. 9,10 (2F)			Symposium 19 Management of Cervical spondylosis by neurologists		O-24 Muscle diseases 2		LS-25 argenx Japan K.K.									
	Room 15 No. 11 (2F)																
Makuhari Messe	Poster Session / Exhibition			Poster Preparation / Poster Viewing				Poster Viewing					Poster Presentation / Discussion		Poster Removal		



		7:00	8:00	9:00	10:00	11:00	12:00	13:00	14:00	15:00	16:00	17:00	18:00	19:00	20:00	21:00	
Makuhari Messe International Conference Hall	Room 1 Convention Hall (2F)		Web Symposium 26 Expansion of repeat expanded diseases by neurogenetics				LS-26 Mitsubishi Tanabe Pharma Corporation	Web PL-02 Plenary Lecture 02 Speaker: Norina Shahrazada Topic: Yoshikazu Uegawa	Web Neuroscience Frontier Symposium 03 Common and specific pathologies in neurodegeneration								
	Room 2 International Conference Room (2F)		Lecture Marathon LM-07	Lecture Marathon LM-08	Lecture Marathon LM-09		LS-27 Japan Medical Office, Takeda Pharmaceutical Company Limited		Lecture Marathon LM-10	Lecture Marathon LM-11							
	Room 3 201 (2F)		Web Symposium 27 Direct connection of medical care to patients: telemedicine spreads to the future		O-25 Neurogenetics and Gene therapy 1		LS-28 Novartis Pharma K.K.		Web Symposium 30 The Dawn of A New Era Therapy for GNE Myopathy				ES-06 Eisai Co., Ltd.				
	Room 4 301 (3F)		Symposium 28 Prospects and Challenges of Developing Individualized Medicine for Neurological Rare Diseases		O-26 Neuroinfection		LS-29 Alnylam Japan K.K.		2023 Special Symposium Joint symposium by the Japanese Society of Neurology, and Japanese Society of Neurological Therapeutics: To aim accelerate drug development in neurological disorders				ES-07 Medtronic Japan Co., Ltd.				
	Room 5 304 (3F)				O-27 Neurorehabilitation 2								ES-08 Japan Blood Products Organization				
	Room 6 302 (3F)		Web Symposium 29 Women in Neurology in the USA and Japan		O-28 Dementia 4		LS-30 Otsuka Pharmaceutical Co., Ltd.		Symposium 31 Lessons Learned from Imaging on Clinical Issues in Parkinson's Disease and related disorders				ES-09 IQVIA JAPAN GROUP				
	Room 7 303 (3F)				O-29 Cerebrovascular disease 4		LS-31 AMGEN K.K.		History Session The interesting history of neurology								
	Room 8 103 (1F)				O-30 Motor neuron disease 3		LS-32 ZENYAKU KOGYO CO., LTD.										
	Room 9 104 (1F)				O-31 Peripheral neuropathy and Metabolic disorders 3		LS-33 Splink, Inc.										
	Room 10 105 (1F)				O-32 Muscle diseases 3		LS-34 GlaxoSmithKline K.K.										
Tokyo Bay Makuhari Hall	Room 11 No. 3,4 (2F)		Hot Topics 06 Development of the basic research using human brain tissues		O-33 Clinical Neurophysiology		LS-35 ONO PHARMACEUTICAL CO., LTD.										
	Room 12 No. 5,6 (2F)		New Guideline 01 Interpretation of the Stroke Treatment Guidelines 2021 and New Evidence		O-34 Parkinsonism and Related disorders 3		LS-36 Alexion Pharmaceuticals, Inc.		New Guideline 02 Japanese Best Practice Recommendations for ALS 2022: Report from the Subcommittee of the Japanese Society of Neurology								
	Room 13 No. 7,8 (2F)				O-35 Cerebrovascular disease 5		LS-37 CHUGAI PHARMACEUTICAL CO., LTD.										
	Room 14 No. 9,10 (2F)				O-36 Neuroimmunology 4		LS-38 Biogen Japan Ltd.										
	Room 15 No. 11 (2F)																
Makuhari Messe	Poster Session / Exhibition		Poster Preparation / Poster Viewing					Poster Viewing				Poster Presentation / Discussion		Poster Removal			

		7:00	8:00	9:00	10:00	11:00	12:00	13:00	14:00	15:00	16:00	17:00	18:00	19:00	20:00	21:00										
Makuhari Messe International Conference Hall	Room 1 Convention Hall (2F)		[Web] New Guideline 03 Beyond the clinical practice guideline for epilepsy			O-37 Epilepsy		LS-39 Eisai Co., Ltd.				[Web] O-39 Chong Geronium														
	Room 2 International Conference Room (2F)		[Web] Symposium 32 Functional neurological disorders: updates and the role of neurologists			MSO-01 Medical Staff Award Nominee Session		LS-40 Daiichi Sankyo Co., Ltd.			[Web] Resident Clinical Tournament															
	Room 3 201 (2F)		[Web] Neuroscience Frontier Symposium 04 Tauopathies: Pathomechanism and management strategies			O-38 Parkinsonism and Related disorders 4		LS-41 AbbVie GK																		
	Room 4 301 (3F)		Symposium 33 The forefront of development in collaboration with the regulatory authorities and ARO in neurological disorders.			StO-01 Students and Junior Residents Oral Session-01 (Oral Presentation Award Session)	StO-04 Students and Junior Residents Oral Session-04	LS-42 Bristol-Myers Squibb/Pfizer Japan Inc.																		
	Room 5 304 (3F)		Symposium 34 Current Progress in Reproductive Medicine and Neurology			StO-02 Students and Junior Residents Oral Session-02	StO-05 Students and Junior Residents Oral Session-05																			
	Room 6 302 (3F)		[Web] Hot Topics 07 Migraine: Pathophysiology and the paradigm shift of management			StO-03 Students and Junior Residents Oral Session-03	StO-06 Students and Junior Residents Oral Session-06	LS-43 ONO PHARMACEUTICAL CO., LTD.																		
	Room 7 303 (3F)		Symposium 35 Present and future of Segawa Disease; 50th memorial symposium for discover of Segawa disease				O-39 Parkinsonism and Related disorders 5		LS-44 Asahi Kasei Medical Co., Ltd.																	
	Room 8 103 (1F)						O-40 Neuroimmunology 5		LS-45 Anylam Japan K.K.																	
	Room 9 104 (1F)						O-41 Neuroimmunology 6		LS-50 Eli Lilly Japan K.K.																	
	Room 10 105 (1F)						O-42 Neurorehabilitation 3																			
Tokyo Bay Makuhari Hall	Room 11 No. 3,4 (2F)		Symposium 36 Differential diagnosis of neuropathies that lead to treatment			O-43 Peripheral neuropathy and Metabolic disorders 4		LS-46 Sumitomo Pharma Co., Ltd.																		
	Room 12 No. 5,6 (2F)		Lecture Marathon LM-12 Lecture Marathon LM-13			O-44 Neuroimaging		LS-47 Pfizer Japan Inc.																		
	Room 13 No. 7,8 (2F)		Symposium 37 Dawn of Telestroke			O-45 Cerebrovascular disease 6		LS-48 Biogen Japan Ltd.																		
	Room 14 No. 9,10 (2F)					O-46 Neurogenetics and Gene therapy 2		LS-49 argenx Japan K.K. Medical Affairs																		
	Room 15 No. 11 (2F)																									
Makuhari Messe	Poster Session / Exhibition	Exhibition Hall7 (1F)	Poster Preparation / Poster Viewing													Poster Viewing	Poster Presentation / Discussion	Poster Removal								